Skip to main navigation
Contact
Company
About Us
Leadership Team
Board of Directors
Collaborations
State Regulations/Disclosures
Contact
Our Focus
Structure-Guided Drug Design
Rare Disease Therapeutics
Rare Disease Patient Communities
Our Products
Our Programs
Pipeline
Complement Program
FOP Program
Galidesivir
Medical Affairs
Request for Medical Information
Request for Medical Education Grants
External Research Program
Expanded Access Program/Policy
Clinical Trial Data Transparency
Careers
Career Openings
Culture
Investors & Media
Corporate Profile
Analyst Coverage
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Historic Stock Lookup
Investment Calculator
Finance & Filings
Financial Profile
SEC Documents
Corporate Governance
Highlights
Committee Composition
Code of Business Conduct
Committee Charters
Investor FAQs
Proxy Online
Countries
United Kingdom
United States
Germany
France
Nordics
Contact
Investors & Media
Corporate Profile
Analyst Coverage
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Historic Stock Lookup
Investment Calculator
Finance & Filings
Financial Profile
SEC Documents
Corporate Governance
Highlights
Board of Directors
Committee Composition
Code of Business Conduct
Committee Charters
Investor FAQ
Proxy Online
Investor Relations
John Bluth
+1 919.859.7910
investorrelations@biocryst.com
Investor Tools
Shareholder Tools
Print Page
Printed Materials
Email Alerts
RSS News Feeds
Share Page
Event Details
BCX9250 Phase 1 Results
Dec 21, 2020
Facebook
LINKEDIN
TWITTER
RSS
